AstraZeneca’s Tagrisso cuts the risk of EGFR-Positive Lung Cancer Patients Developing Brain Metastases.

Osimertinib (trade name Tagrisso) is a medication used to treat non-small-cell lung carcinomas with specific mutations. It belongs to the 3'rd generation of EGFR tyrosine kinase inhibitors. Osimertinib was developed by AstraZeneca in order to treat locally advanced or metastatic NSCLC (non-small-cell lung cancer), if the cancer cells are positive for the T790M mutation in the gene coding for the epidermal growth factor receptor or for activating the EGFR mutations. The T790M mutation can be acquired after the first-line treatment with the other TKIs, such as gefitinib, afatinib and erlotinib. 

This medication has been shown a clinically impactful improvement in the central nervous system (CNS) disease-free survival (DFS) in order to treat patients with the early-stage EGFR-positive NSCLC after complete tumour resection.
The outcomes, from the ADAURA phase-3 trial, were popped up at the 2020 European Society for Medical Oncology (ESMO) virtual congress and also simultaneously published in The New England Journal of Medicine.

The detailed outcomes represented that the treatment with Tagrisso is able to reduce the risk of the CNS recurrence or death by 82%.
The executive vice president of Oncology R&D at AZ, José Baselga stated that, "This medication has potential to prevent the development of brain metastases in patients with the early disease and reinforce." 
"This medicine is truly transformative for the patients who are with EGFR-mutated lung cancer", José Baselga added.